Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2016-12-20
- Target Recruit Count
- 90
- Registration Number
- NCT02998827
The Effective and Safety of Thalidomide in NTDT
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Xiao-Lin Yin
- Target Recruit Count
- 30
- Registration Number
- NCT02995707
- Locations
- 🇨🇳
NO.3 Hospital of the Chinese People's Liberation Army, Nanjing, Guangxi, China
Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02966522
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2016-11-06
- Target Recruit Count
- 72
- Registration Number
- NCT02956538
- Locations
- 🇨🇳
Department of Gastroenterology, Guangzhou, Guangdong, China
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 124
- Registration Number
- NCT02891811
- Locations
- 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 243
- Registration Number
- NCT02870036
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijin, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2019-06-14
- Target Recruit Count
- 55
- Registration Number
- NCT02858804
- Locations
- 🇨🇳
Shuhua Yi, Tianjin, China
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2016-07-26
- Target Recruit Count
- 44
- Registration Number
- NCT02844309
- Locations
- 🇨🇳
Shuhua Yi, Tianjin, China
Conmana Combined With Thalidomide to Treat NSCLC
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Henan Provincial People's Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT02778893
- Locations
- 🇨🇳
XZhang, Zhengzhou, Henan, China
Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Registration Number
- NCT02754960
- Locations
- 🇨🇳
Gastroenterology department; Ren Ji Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.